Answers are grounded in this paper and cite their sources.
Precision medicine has transformed healthcare by moving toward individualized treatment strategies, yet dosing optimization for pediatric patients remains a complex challenge. Therapeutic drug monitoring (TDM), a widely used practice in clinical settings, provides a foundation for achieving therapeutic goals but poses significant limitations, particularly in the pediatric population, due to the frequent need for blood sampling and delayed adjustments. Model‐informed precision dosing (MIPD) is an emerging strategy that combines population pharmacokinetic (pop‐PK) models with patient‐specific data to enhance therapeutic outcomes while minimizing the need for invasive procedures. This narrative review highlights the potential of MIPD in pediatric antimicrobial therapy, with an emphasis on its applications, advantages, and current challenges. By analyzing recent advancements in pop‐PK models for antimicrobials, this review article underscores MIPD’s ability to optimize dosing strategies and improve clinical outcomes for pediatric patients. Despite the barriers to widespread implementation, such as data availability and regulatory hurdles, MIPD offers a path forward for precision medicine in pediatrics. By bridging the gap between computational modeling and clinical practice, MIPD has the potential to reshape the future of pediatric pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Kai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: